<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02945462</url>
  </required_header>
  <id_info>
    <org_study_id>EDUJCTC</org_study_id>
    <nct_id>NCT02945462</nct_id>
  </id_info>
  <brief_title>Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)</brief_title>
  <official_title>The Safety and Efficacy of Using Bone Marrow-derived Mesenchymal Stem Cells in the Treatment of Erectile Dysfunction in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jordan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jordan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recovery of erectile function using bone marrow mesenchymal stem cells (MSCs) after in vitro&#xD;
      expansion under restricted culturing conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four diabetic male patients ranging from 25-65 years diagnosed with erectile dysfunction will&#xD;
      be selected. This diagnosis is based on medical history, validated questionnaires, physical&#xD;
      examinations, laboratory tests and specific diagnostic tests. Patients with any evidence of&#xD;
      untreated hypogonadism, current urinary tract or bladder infection, clinically evident penile&#xD;
      anatomical deformities, previous penile implant or penile vascular surgery, uncontrolled&#xD;
      hypertension or hypotension, reported unstable Cardiovascular diseases, uncontrolled diabetes&#xD;
      (HbA1c &gt; 10%), or primary hyperlipidemia will be excluded. The investigators hypothesize that&#xD;
      the intracavernous injection of stem cells will facilitate the recovery of erectile function&#xD;
      resulting in satisfying clinical outcomes in patients.&#xD;
&#xD;
      This study was performed:&#xD;
&#xD;
        1. To test the safety of autologous intracavernous bone marrow mesenchymal stem cells.&#xD;
&#xD;
        2. To evaluate benefit for the patient concerning recovery of natural erection by&#xD;
           performing detailed and specific diagnostic tests prior and post MSCs injection by a&#xD;
           team from Jordan University Hospital and Cell Therapy Center in Jordan University.&#xD;
&#xD;
        3. To study the feasibility, indication criteria and application modalities of Bone marrow&#xD;
           mesenchymal stem cells for further wider study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>six months</time_frame>
    <description>Observation of any relevant adverse side effect resulting from the injection. Assessing the safety of autologous Mesenchymal Stem Cells injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment the efficacy of intracavernous injection measured by SHIM/IIEF/EHS questionnaire</measure>
    <time_frame>18 months</time_frame>
    <description>Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells by Sexual Health Inventory for Men/ International Index for Erectile Function/ Erection Hardness Score (SHIM/IIEF/EHS) questionnaire.&#xD;
For every patient tests would be performed at baseline and repeated at 1,3, 6,12, and 18 months post-injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation the efficacy of intracavernous injection measured by Dynamic Infusion cavernosometry test.</measure>
    <time_frame>6 months</time_frame>
    <description>Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells by Dynamic Infusion Cavernosometry test at baseline and repeated at 6 months post injection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>autologous mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:&#xD;
Autologous bone marrow derived stem cells will be injected twice intracavernously to enrolled erectile dysfunction patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous mesenchymal stem cells</intervention_name>
    <description>Patients will be injected with autologous mesenchymal stem cells, intracavernously</description>
    <arm_group_label>autologous mesenchymal stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult male patients ranging from 25 to 65 years.&#xD;
&#xD;
          2. Type 1 or type 2 diabetic patients with a personal history of diabetes ≥ 5 years.&#xD;
&#xD;
          3. History of chronic erectile dysfunction for at least six months.&#xD;
&#xD;
          4. HbA1c ≤ 10%.&#xD;
&#xD;
          5. Baseline International Index of Erectile Function (IIEF) score of &lt; 26.&#xD;
&#xD;
          6. Not interested or able to use Phosphodiesterase type 5 inhibitor (PDE-5i) drug therapy&#xD;
             and willing to forgo these treatments for the first 6 month period following study&#xD;
             treatment.&#xD;
&#xD;
          7. Body mass index between 20 -30.&#xD;
&#xD;
          8. Willing to provide written informed consent, complete questionnaire, and to be&#xD;
             available for all baseline treatment and follow up examinations required by protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Untreated hypogonadism or low serum total testosterone &lt; 200 ng/dl.&#xD;
&#xD;
          2. Current urinary tract or bladder infection.&#xD;
&#xD;
          3. Any medical evidence of any infectious disease.&#xD;
&#xD;
          4. Clinically evident penile anatomical deformities (e.g., Peyronie's disease) or history&#xD;
             of priapism.&#xD;
&#xD;
          5. Skin irritation, infection, wound, sore or disruption in the immediate areas of skin&#xD;
             entry for penile injection.&#xD;
&#xD;
          6. Current or previous malignancy.&#xD;
&#xD;
          7. Patients with primary hyperlipidemia.&#xD;
&#xD;
          8. Use of any non study treatment for erectile dysfunction within 4 weeks of study&#xD;
             treatment.&#xD;
&#xD;
          9. Lack of willingness to continue through 6 months after study treatment.&#xD;
&#xD;
         10. Any previous penile implant or penile vascular surgery.&#xD;
&#xD;
         11. Uncontrolled hypertension or hypotension (systolic blood pressure &gt; 170 or &lt; 90 mm Hg,&#xD;
             and diastolic blood pressure &gt; 100 or &lt; 50 mm Hg).&#xD;
&#xD;
         12. Reported unstable cardiovascular disease (e.g., unstable angina, myocardial infarction&#xD;
             within past 6 months, cardiac failure or life-threatening arrhythmia, congestive heart&#xD;
             failure) or symptomatic postural hypotension within 6 months before screening.&#xD;
&#xD;
         13. Bleeding or clotting disorder, use of anticoagulant therapy.&#xD;
&#xD;
         14. Lab values for complete blood count, prothrombin time/ partial thromboplastin&#xD;
             time/international randomized ratio (PT/PTT/INR), Aspartate aminotransferase (AST),&#xD;
             alanine aminotransferase (ALT), and creatinine falling outside the normal lab values.&#xD;
&#xD;
         15. Systemic autoimmune disorder.&#xD;
&#xD;
         16. Significant active systemic or localized infection.&#xD;
&#xD;
         17. Receiving immunosuppressant medications.&#xD;
&#xD;
         18. HbA1c &gt; 10%.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jordan</investigator_affiliation>
    <investigator_full_name>Saddam Dmour</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

